Ipamorelin vs Sermorelin: What Differs

The key difference at a glance

The core difference between ipamorelin and sermorelin is the receptor each compound acts on in published laboratory research. Ipamorelin is described in the literature as a selective ghrelin-receptor agonist, meaning it binds the growth hormone secretagogue receptor subtype 1a (GHS-R1a). Sermorelin is a growth-hormone-releasing hormone (GHRH) analogue that acts at a different target, the GHRH receptor (GHRHR). In short, they reach the same part of the pituitary research model by two separate molecular routes.

Both are classed in the scientific literature as growth-hormone secretagogues in the broad sense, because experimental models report that each can prompt the release of endogenous growth hormone from pituitary somatotrophs. However, ipamorelin belongs to the growth hormone releasing peptide (GHRP) family, while sermorelin is a shortened fragment of a naturally occurring hormone. This distinction in class and receptor target is what most published comparisons focus on.

The sections below set out each mechanism as reported in research, how the two compare, what the peptide-class and structural literature records, and the current regulatory and anti-doping status in Australia. All information here is educational and relates to laboratory research compounds only.

Ipamorelin: a selective ghrelin-receptor agonist

Ipamorelin is a synthetic pentapeptide first described by Raun and colleagues in 1998. In the research literature it is characterised as a ghrelin-receptor (GHS-R1a) agonist, placing it in the growth hormone releasing peptide (GHRP) family alongside compounds such as GHRP-6. GHS-R1a is the same receptor that the endogenous hormone ghrelin, identified by Kojima and colleagues in 1999, acts upon.

In experimental models, activation of GHS-R1a on pituitary somatotrophs is reported to prompt pulsatile release of growth hormone. Ipamorelin is frequently cited in comparison studies because early animal data described it as a potent GH-releasing agent in those models. These findings are reported as research observations in laboratory and animal settings and are not statements about any outcome in people.

Ipamorelin research overview

Sermorelin: a GHRH analogue

Sermorelin is a GHRH analogue. Specifically, it corresponds to the first 29 amino acids of human growth-hormone-releasing hormone, a hormone that in its full form is 44 residues long. This 1-29 segment is often described in the literature as the shortest N-terminal fragment that retains the functional activity of the parent hormone, and the synthetic peptide is commonly prepared in an amidated form written as GRF(1-29)-NH2.

Rather than acting on the ghrelin receptor, sermorelin binds the GHRH receptor (GHRHR), which belongs to the class B family of G-protein-coupled receptors and is expressed on pituitary somatotrophs. Research descriptions note that receptor binding initiates a signalling cascade associated with the release of endogenous growth hormone in experimental models. Because sermorelin mimics a fragment of a naturally occurring hormone, it is often grouped with GHRH-type research peptides rather than with the GHRP secretagogues.

Sermorelin acetate research overview

How the two mechanisms compare

Although ipamorelin and sermorelin are both studied in the context of pituitary growth-hormone release, the published literature treats them as mechanistically distinct. The most useful way to frame the comparison is by receptor, class and origin.

• Receptor: ipamorelin acts at the ghrelin receptor (GHS-R1a); sermorelin acts at the GHRH receptor (GHRHR).
• Peptide class: ipamorelin is a synthetic pentapeptide in the GHRP family; sermorelin is a fragment analogue of the natural hormone GHRH.
• Origin: ipamorelin is a purpose-designed sequence; sermorelin reproduces the 1-29 N-terminal portion of human GHRH.
• Pathway independence: research sources note that sermorelin does not act on the ghrelin-receptor pathway used by GHRPs such as ipamorelin, which is why the two are sometimes studied as separate but complementary research tools.
• Signalling pattern: both are described in experimental models as prompting pulsatile rather than continuous growth-hormone release.

CJC-1295 vs ipamorelin comparison

Selectivity and the broader hormonal picture in research

A recurring theme in the ipamorelin literature is selectivity. The original research reported that, in animal models, ipamorelin produced growth-hormone release without a statistically significant rise in adrenocorticotropic hormone (ACTH) or cortisol, at experimental concentrations well above the threshold for GH release in those animal models. This contrasted with some older GHRPs that were reported to affect additional hormones such as cortisol and prolactin. These are published laboratory and animal findings and should be read as research observations, not as any characterisation of effects in humans.

It is worth noting that the evidence base here is drawn largely from early animal studies and a limited number of later investigations. Some reviews describe human clinical data as limited and note that long-term safety in people is not well established. Readers should treat selectivity claims as descriptions of specific experimental results rather than settled conclusions.

Sermorelin, acting through the GHRH receptor, is studied as a mimic of the body's own releasing hormone. Because it works through a distinct receptor, its reported pharmacology is generally discussed separately from the ghrelin-receptor selectivity questions that surround the GHRP class.

Regulatory status in Australia (TGA and ARTG)

In Australia, growth hormone secretagogues are addressed by the Poisons Standard administered by the Therapeutic Goods Administration (TGA). Ipamorelin appears by name within the growth hormone secretagogue entries captured in Schedule 4 and Appendix D, Part 5 of the Poisons Standard. Schedule 4 is the Prescription Only Medicine category. Sermorelin is a GHRH-type compound and is commonly discussed in the prescription-only context, although it is not named in the same way in the material reviewed here, so its precise listing should be checked directly against the current Poisons Standard.

Neither compound is understood to have a product registered on the Australian Register of Therapeutic Goods (ARTG) for general consumer supply. In practice this means there is no generally-approved consumer medicine for either peptide in Australia. Anyone seeking authoritative detail on scheduling, access pathways or registration should consult the TGA and the federal Poisons Standard directly, as these records are updated over time.

The compounds discussed here are laboratory research materials. They are not consumer products, and the regulatory notes above are provided for educational context only.

WADA anti-doping status

Both compound types are relevant to anti-doping rules. Under the World Anti-Doping Agency (WADA) framework, section S2 covers peptide hormones, growth factors, related substances and mimetics, and it includes growth-hormone-releasing factors. Published editions of the Prohibited List group GHRH analogues such as sermorelin together with growth hormone releasing peptides and secretagogues such as ipamorelin within this class.

Substances in S2 are listed as prohibited at all times, meaning both in and out of competition. Athletes and support personnel subject to anti-doping rules should rely on the current official WADA Prohibited List rather than secondary summaries, since the List is revised annually. The point to take from any comparison is that neither compound sits outside the anti-doping framework.

Molecular and structural notes

From a structural standpoint the two peptides are very different in size and origin, which underlines why they are not interchangeable in research discussions.

• Ipamorelin is a small synthetic pentapeptide, a purpose-designed sequence in the GHRP family.
• Sermorelin is a 29-amino-acid peptide corresponding to the N-terminal 1-29 region of the 44-residue human GHRH, typically prepared as the amidated GRF(1-29)-NH2 form.
• Ipamorelin was first reported in 1998; sermorelin is modelled on a naturally occurring human hormone fragment.
• The two engage separate receptors (GHS-R1a versus GHRHR), so their primary research interest lies in those distinct pathways.